Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mechanisms leading to in vivo ceftazidime/avibactam resistance development during treatment of GES-5-producing Pseudomonas aeruginosa infections.

Antimicrobial agents and chemotherapy - 6 Nov 2024

Herrera Cristhian, Gomis-Font Maria A, López-Causapé Carla, Díez-Aguilar María, Fraile-Ribot Pablo A, Cardeñoso Laura M, Oliver Antonio

Abstract excerpt

The mechanisms underlying ceftazidime/avibactam resistance development in four ceftazidime/avibactam susceptible/resistant pairs of GES-5-producing ST235 Pseudomonas aeruginosa clinical isolates were investigated. In three of the cases, ceftazidime/avibactam resistance was driven by a single mutation leading to GES-27 (P162Q), GES-29 (P162A), or the novel GES-60 (N136S), as confirmed through cloning experiments....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azabicyclo Compounds
Share to beta-Lactamases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carbapenems

Share to Ceftazidime

Share to Cephalosporins

Share to Drug Combinations

Share to Imipenem

Share to Pseudomonas Infections

Source

Open in PubMed Open full text

Identifiers

PMID: 39431817
DOI: 10.1128/aac.01164-24
PMCID: PMC11539206

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mechanisms leading to in vivo ceftazidime/avibactam resistance development during treatment of GES-5-producing Pseudomonas aeruginosa infections.PMID 39431817Read ↗

Acquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in Pseudomonas aeruginosaSemantic proximity Read ↗

Mutations leading to ceftolozane/tazobactam and imipenem/cilastatin/relebactam resistance during in vivo exposure to ceftazidime/avibactam in Pseudomonas aeruginosaSemantic proximity Read ↗

In vivo translational assessment of the GES genotype on the killing profile of ceftazidime, ceftazidime/avibactam and meropenem against Pseudomonas aeruginosa.Semantic proximity Read ↗

GES-18, a New Carbapenem-Hydrolyzing GES-Type β-Lactamase from Pseudomonas aeruginosa That Contains Ile80 and Ser170 ResiduesSemantic proximity Read ↗

Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC.Semantic proximity Read ↗

Resistance to ceftazidime–avibactam and underlying mechanismsSemantic proximity Read ↗

Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam inPseudomonas aeruginosaisolates recovered from ICU patients in Spain and Portugal depicted by WGSSemantic proximity Read ↗

Emergence of GES-19-producing Pseudomonas aeruginosa exoU+ belonging to the global high-risk clone ST235 in cystic fibrosis infection.Semantic proximity Read ↗

Unexpected Challenges in Treating Multidrug-Resistant Gram-Negative Bacteria: Resistance to Ceftazidime-Avibactam in Archived Isolates of Pseudomonas aeruginosaSemantic proximity Read ↗

Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical Pseudomonas aeruginosa isolates from SwitzerlandSemantic proximity Read ↗

Mutation-Driven Evolution of Pseudomonas aeruginosa in the Presence of either Ceftazidime or Ceftazidime-Avibactam.Semantic proximity Read ↗

In Vivo Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated PathwaysSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.